Is there a drug-drug interaction between darunavir/ritonavir and raltegravir?

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 1, 2012, Pages

  Fabbiani, Massimiliano ^a   Navarra, Pierluigi ^a   Cauda, Roberto ^a   De Luca, Andrea ^a,b   Di Giambenedetto, Simona ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; ENFUVIRTIDE; RALTEGRAVIR; TENOFOVIR;

AREA UNDER THE CURVE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIRUS LOAD;

ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; PYRROLIDINONES; RITONAVIR; SULFONAMIDES;

EID: 84862135844     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31824dd76d     Document Type: Letter

References (15)

1. Jackson A, Watson V, Back D, et al. Plasma and intracellular pharmacokinetics of darunavir/ ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals. J Acquir Immune Defic Syndr. 2011;58: 450-457.
2. Prezista, Summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000707/WC500041756.pdf. Accessed November 14, 2011.
3. Isentress, Summary of product characteristics Available at: http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Product- Information/human/000860/WC500037405.pdf. Accessed November 14, 2011.
4. Fabbiani M, Di Giambenedetto S, Ragazzoni E, et al. Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction. Pharmacol Res. 2011;63:249-253.
5. Cattaneo D, Gervasoni C, Cozzi V, et al. Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients. Pharmacol Res. 2012;65:198-203.
6. Garvey L, Latch N, Erlwein OW, et al. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir- boosted darunavir in HIV type-1-infected patients. Antivir Ther. 2010;15:213-218.
7. Goldwirt L, Braun J, de Castro N, et al. Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIERANRS 138 trial. Antimicrob Agents Chemother. 2011;557:3613-3615.
8. Cianfriglia M, Dupuis ML, Molinari A, et al. HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. Retrovirology. 2007;4:17.
9. Zembruski NC, Büchel G, Jödicke L, et al. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J Antimicrob Chemother. 2011;66: 802-812.
10. Zhu L, Butterton J, Persson A, et al. Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals. Antivir Ther. 2010;15:1107-1114.
11. Boffito M, Miralles D, Hill A. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and-experienced patients. HIV Clin Trials. 2008; 9:418-427.
12. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339-354.
13. Taiwo B, Zheng L, Gallien S, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (AIDS Clinical Trials Group A5262). AIDS. 2011;25:2113-2122.
14. Bedimo R, Drechsler H, Turner D, et al. RADAR study: raltegravir combined with boosted darunavir has similar safety and antiviral efficacy as tenofovir/emtricitabine combined with boosted darunavir in antiretroviral naive patients. Paper presented at: 6th IAS Conference on HIV Pathogenesis Treatment and Prevention; July 17-20, 2011; Rome, Italy.
15. NEAT-European AIDS Treatment Network. Study of darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir in HIV-infected antiretroviral naïve subjects (ANRS 143). Available at: http://clinicaltrials.gov/ct2/show/ NCT01066962. Accessed November 14, 2011.